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Abstract The present study was designed to investigate whether
and how the purinergic stimulation of rat ventricular myocytes
modulates the cAMP-dependent pathway. Stimulation of cardi-
omyocytes with ATPQS in the presence of the phosphodiesterase
inhibitor IBMX increases by 3-fold intracellular cAMP content.
In contrast to L-adrenergic stimulation, the purinergic stimula-
tion of adenylyl cyclase was not inhibited by activation or
enhanced by inhibition of a Gi protein. Forskolin did not
potentiate the effect of extracellular ATPQS on intracellular
cAMP content but the effect of isoproterenol did. Like
isoproterenol, the purinergic agonist decreased subsequent
ADP-ribosylation of a 45 kDa GKs by cholera toxin. ATPQS
also increased cAMP content in neonatal rat cardiomyocytes, a
cell type that expresses a long form of Gs protein (Ks, 52 kDa) in
contrast to adult rat cardiomyocytes that express mostly a short
form of Gs protein (Ks, 45 kDa). Both purinergic and L-
adrenergic agonists increased cAMP in HEK 293 cells expres-
sing type V adenylyl cyclase while cAMP was only increased by
L-adrenergic stimulation of HEK expressing type IV or VI
adenylyl cyclases. Thus, we propose that the purinergic and L-
adrenergic stimulations differentially activate adenylyl cyclase
isoforms in rat cardiomyocytes and that adenylyl cyclase V is the
specific target of the purinergic stimulation.
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1. Introduction
Extracellular purines have been recognized for many years
to exert various and potent actions on the cardiovascular
system (for review, [1,2]). These actions are mediated by dif-
ferent subtypes of purinergic receptors, namely the P1-purino-
ceptor with high a⁄nity for adenosine and the P2-receptor
that is preferentially activated by ATP and ADP. Further-
more, P2-purinoceptors can be classi¢ed into di¡erent sub-
types, such as P2X, P2Y, P2Z, P2T and P2U [3]. The pharmaco-
logical and molecular classi¢cations of these latter is still
under debate while the cloning of numerous P2X and P2Y is
under progress [3]. A least four P2X (i.e. P2X1, P2X3, P2X4,
P2X5) and four P2Y (i.e. P2Y1, P2Y2, P2Y4, P2Y6) receptors
were already found in heart [4] suggesting that purines exert
a major regulation of cardiac function.
ATP, released from nerve terminals under physiological sit-
uations or from cardiomyocytes, endothelial cells, smooth
muscle cells and platelets under pathological conditions have
multiple cellular e¡ects. In the heart, the purine increases con-
tractility of isolated cardiac preparations [5]. It induces a tran-
sient acceleration and then slows down the sinus pacemaker
leading to a negative chronotropic and dromotropic e¡ect on
the mammalian sinoatrial node. In ischemic hearts, ATP
could also be a source of arrhythmia [2]. To better understand
the mechanism of action of the purinergic agonist on cardiac
function, the dissection of intracellular signaling pathways
activated by ATP is of major interest.
Extracellular ATP triggers the breakdown of phosphoinosi-
tides in most cell types [6] including cardiomyocytes leading to
IP3 formation [5,7] and PKC activation [8]. The purine also
activates a tyrosine kinase-dependent pathway [9]. In some
cell types, including hepatocytes [10], platelets [11] and glioma
cells [12], ATP decreases intracellular cAMP through activa-
tion of a pertussis toxin-sensitive G protein while in others
such as endothelial cells [13] or neuronal NG108 cells [14] the
purine is a potent activator of adenylyl cyclase leading to an
increase in intracellular cAMP. Whether ATP does a¡ect in-
tracellular cAMP levels in cardiac cells is still controversial.
Zheng et al. [15] observed that ATP does not a¡ect basal
cAMP content of rat ventricular cardiomyocytes but further
increases the L-adrenergic receptor-mediated cAMP rise. On
the contrary, Yamada et al. [7] used cardiomyocytes isolated
from fetal mice and found a decrease in isoproterenol-induced
cAMP increase by ATP but no signi¢cant e¡ect of the purine
when applied alone to the cells. We thus decided to reconsider
the question as to whether ATP modulates the cAMP-depend-
ent pathway in rat cardiomyocytes. In the present study, we
have used di¡erent approaches to modulate basal content of
intracellular cAMP to further investigate the e¡ect of P2-pu-
rinergic stimulation on cyclic nucleotide levels in isolated car-
diomyocytes. We found that purinergic stimulation of cardi-
omyocytes does signi¢cantly increase intracellular cAMP.
This e¡ect was additive to increases induced by isoproterenol
but was not counteracted by Gi protein stimulation. Puriner-
gic and L-adrenergic stimulations of transiently transfected
HEK 293 cells that express speci¢c adenylyl cyclase isoforms
showed that adenylyl cyclase type V is speci¢cally activated by
the purine. This concept as to a speci¢c targeting of an ad-
enylyl cyclase isoform that we found in both cardiac cells and
in the HEK 293 cell line could be extended to other cell types
that express purinergic receptors.
2. Materials and methods
2.1. Cardiomyocyte isolation
Cardiomyocytes were isolated from hearts of 200^250 g male Wis-
tar rats as previously described [16]. Brie£y, the hearts were ¢rst
perfused at 35‡C with a nominally Ca2-free HEPES-bu¡ered solu-
tion for 5 min and then for 55 min with the same solution containing
1.2^1.5 mg/ml collagenase (Type A, Boehringer) and 20^25 WM Ca
adjusted with a Ca2 ion-selective electrode. The heart was removed
from the perfusion set-up and gently dissociated through the bore of a
large tip pipette. After ¢ltration, the cells were allowed to decant and
the pellet was resuspended in collagenase-free HEPES solution. The
cells were incubated for 15 min at 37‡C. Meanwhile Ca2 concentra-
tion was increased stepwise up to 0.3 mM. Cells were then washed and
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resuspended in HEPES solution containing 1 mM Ca and 0.25% BSA.
Six to eight 106 rod-shaped cells/heart were routinely obtained. Dis-
sociation giving a low yield of viable cells were discarded.
2.2. Culture of neonatal rat cardiomyocytes
Myocytes were isolated from the ventricles of 2^3 days old rat
hearts using 0.4 mg/ml collagenase (Worthington type II) and
0.6 mg/ml pancreatin according to Iwaki et al. [17] in HEPES-bu¡ered
solution containing 116 mM NaCl, 20 mM HEPES, 0.8 mM
Na2HPO4, 5.4 mM KCl, 0.8 mM MgSO4, 5.6 mM glucose, adjusted
at pH 7.35 at room temperature. The cardiomyocytes were puri¢ed on
a Percoll gradient and plated in maintenance medium (DMEM/M199
(4:1 v/v) containing 100 U/ml penicillin and streptomycin) supple-
mented with 10% horse serum and 5% fetal calf serum. Cells were
serum starved overnight before agonist stimulation.
2.3. Transfection of HEK 293 cells
HEK 293 cells were cultured in DMEM supplemented with 10%
fetal calf serum. The cells plated in 35 mm dishes were transfected
with 10 Wg/ml of DOTAP and 2 Wg of plasmids encoding type IV, V
or VI adenylyl cyclases. Type IV was subcloned in pBFP cDNA
vector (Clontech) using the EcoRI and NotHI restriction sites. After
48 h, the cells were serum starved for 1 h before stimulation with
agonists.
2.4. Measurement of intracellular cAMP
Cells were preincubated for 10 min in the presence of 0.1 mM
IBMX. Batches of 250 000 cardiac cells or dishes of HEK 293 (50%
con£uency) were incubated for 5 min at 37‡C with 100 WM ATPQS,
1 WM isoproterenol, and/or with 10 WM forskolin. Incubations were
stopped by addition of perchloric acid. After centrifugation, the pellet
was dissolved in NaOH and used to estimate protein content accord-
ing to Bradford [18]. The supernatant was neutralized by K2CO3 and
the perchlorate precipitate was spun down. An aliquot of the super-
natant was used for cAMP assay. A high speci¢c binding protein
assay kit (Amersham) was used to determine cAMP content. Results
were expressed as pmoles cAMP/mg cell protein.
2.5. Pertussis toxin treatment of cells
Isolated adult rat cardiomyocytes were incubated for 4 h with 300
ng/ml of pertussis toxin. Such a treatment was previously shown to
inhibit by 75% subsequent ADP-ribosylation by the toxin [19]. Some
experiments were also performed using cells incubated for 20 h at
37‡C in the presence of 100 ng/ml of pertussis toxin. Under the latter
condition, 100% of subsequent ADP-ribosylation was inhibited [19].
For such a purpose, cells were suspended in serum-free culture me-
dium (DMEM/M199 4:1 v/v) and were plated at a density of 3U105
cells/60 mm plastic dishes and allowed to attach to the plastic for 1 h.
The dishes were washed twice and fresh medium containing the toxin
was added. Cells were kept overnight under 10% CO2.
2.6. ADP-ribosylation of Gs
Cardiac crude membranes were prepared from isolated adult and
3 days cultured neonatal cells as already described [20]. ADP-ribosyl-
ation of Gs protein was carried out according to Hilal-Dandan et al.
[19] with preactivated cholera toxin.
2.7. SDS-PAGE and Western blotting of Gs protein
Cardiac membrane proteins (100 Wg) were loaded on 10% acryl-
amide gel and run overnight according to Laemmli [21]. The gels
were stained, destained, dried and 32P content was analyzed by auto-
radiography on NEN ¢lms. Bands on ¢lms were quanti¢ed using an
imaging system (SCION IMAGE). Western blotting was performed as
already described [16] using an anti-Ks antiserum.
2.8. Statistics
Statistical signi¢cance was assessed as appropriate by a Student’s t-
test with a signi¢cant di¡erence as being established at P9 0.05.
3. Results
3.1. Purinergic stimulation of cardiac cells increases
intracellular cAMP content
The ¢rst part of this study was aimed at investigating the
e¡ect of a purinergic stimulation of cardiomyocytes on basal
intracellular cAMP content. Basal cAMP content of isolated
rat cardiomyocytes incubated for 10 min at 37‡C in the pres-
ence of 100 WM IBMX was 12 þ 2 pmoles/mg protein (n = 38
out of 19 heart experiments). Purinergic stimulation of cells
for 5 min by 100 WM ATPQS, a poorly hydrolysable analog of
ATP increased by 3-fold intracellular cAMP content (Fig.
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Fig. 1. E¡ects of extracellular ATP on intracellular cAMP content
of isolated cardiomyocytes is mediated by a Gs protein. Adult rat
cardiomyocytes were incubated for 10 min in the presence of IBMX
and then stimulated for 5 min with 100 WM ATPQS. A: The graph
shows the mean þ S.E.M. of 19 experiments performed in duplicate.
The inset shows a dose response curve (mean þ S.E.M. of three ex-
periments). B: Top panel: 200 Wg of membrane protein from adult
cardiomyocytes (lane 1) or 4 Wg of puri¢ed recombinant Ks45 (lane
2) or 150 Wg of membrane protein from neonatal cardiomyocytes
maintained in culture for 3 days (lane 3) were run in SDS-PAGE.
The Western blots were probed with an anti-Ks antiserum and the
G protein was revealed using ECL detection. Molecular mass stand-
ards are shown on the right. Bottom panel: membrane proteins pre-
pared from adult rat cardiomyocytes not stimulated (lane 1), stimu-
lated for 1 min with 1 WM isoproterenol (lane 2), or 100 WM
ATPQS (lane 3) were treated with cholera toxin and [32P]NAD. Pro-
teins were then run in SDS-PAGE; the gel was dried and exposed
for 24 h to autoradiography ¢lms. The arrow indicates the 45 kDa
Ks subunit. Quantitation of the number of pixels per band after
background substraction was 7231, 4059 and 3082 for lanes 1 to 3,
respectively. Similar results were obtained in two other experiments.
C: E¡ects of ATPQS and isoproterenol on intracellular cAMP con-
tent of neonatal rat cardiomyocytes. Neonatal cells maintained in
culture for 3 days were serum starved overnight and stimulated with
100 WM ATPQS or 1 WM isoproterenol or both in the presence of
IBMX. The experiment was performed in three di¡erent cultures
with similar results. Statistically signi¢cant, *P9 0.05; **P9 0.01.
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1A). Cellular cAMP content went up to 38.0 þ 5 pmoles/mg
protein (n = 38 out of 19 experiments). No further increase
was observed when cells were stimulated for 15 min with
the agonist. The EC50 for the e¡ect was 15 WM and 100 WM
of the agonist was required to obtain a maximal stimulation
(inset of Fig. 1A). The same purinergic e¡ect was observed
when milrinone (3 WM) together with RO-20-1724 (10 WM)
replaced IBMX to inhibit phosphodiesterases (4 þ 0.6-fold
stimulation, n = 3).
3.2. ATPQS-induced rise in intracellular cAMP is mediated by
a Gs protein
Preliminary experiments using pharmacological kinase in-
hibitors or intracellular Ca2 chelators have excluded the in-
volvement of a protein kinase (e.g. protein kinase C, tyrosine
kinase or a Ca2-dependent kinase) in the purinergic increase
in cAMP. The use of indomethacin as an inhibitor of cyclo-
oxygenase and in turn of prostaglandin formation ruled out
the possibility that ATPQS increases cAMP in cardiac cells
through a autocrine/paracrine e¡ect as previously shown in
MDCK cells [22]. Thus, two experimental approaches were
used to speci¢cally investigate whether ATPQS could exert
its enhancing e¡ect on intracellular cAMP content by directly
activating a Gs protein.
We ¢rst performed experiments designed to identify the Gs
protein switched on by both the purinergic and the L-adrener-
gic stimulations. Both a 45 and a 52 kDa GKs protein are
expressed in cardiomyocytes. The 45 kDa protein would be
the major isoform in adult rat heart [23,24] although this is
still controversial (see [25]). The 52 kDa protein would be
expressed in a higher amount in neonatal rat hearts [24]. Us-
ing an anti-GKs antiserum, Western blot analysis of membrane
proteins prepared from isolated adult rat cardiomyocytes
showed that the 45 kDa GKs isoform is predominantly ex-
pressed in adult cardiomyocytes while the 52 kDa protein is
the major isoform in neonatal rat cardiomyocytes (Fig. 1B).
Stimulation of adult rat cardiomyocytes for 5 min with 100
WM ATPQS decreased by 49 þ 10% (n = 3) the subsequent
ADP-ribosylation by cholera toxin. Cell stimulation with
1 WM isoproterenol decreased by 52 þ 7% (n = 3) ADP-ribosyl-
ation of Ks (Fig. 1B). This e¡ect was not increased by additive
purinergic stimulation (54 and 56% decrease in two separate
experiments). As an alternative approach to ¢nd out the Gs
protein involved in the purinergic induction of cAMP forma-
tion, we used neonatal cells as a cell type that expresses
mainly the 52 kDa to look at the e¡ect of ATPQS on intra-
cellular cAMP values. In this cell model, the purinergic stim-
ulation also increased cAMP. The purinergic e¡ect was addi-
tive to the isoproterenol enhancing e¡ect on intracellular
cAMP (Fig. 1C). These ¢ndings suggest that both the GKs45
and the GKs52 proteins mediate purinergic activation of ad-
enylyl cyclase.
3.3. L-adrenergic and purinergic agonists use di¡erent pathways
to rise the cAMP content of cardiomyocytes
The increase in cAMP induced by a maximal concentration
of ATPQS was additive to isoproterenol-triggered rise in
cAMP (see Fig. 1C). To further investigate this point, cells
were stimulated with forskolin to fully activate the adenylyl
cyclase, in the presence or absence of the agonists, ATPQS or
isoproterenol. When added separately to cell suspensions, the
purine and forskolin, both used at maximal concentrations,
increased by 3- and 10-fold, respectively, intracellular cAMP
content. When ATPQS and forskolin were added together,
intracellular cAMP was not further enhanced. On the con-
trary, L-adrenergic stimulation of cells with 1 WM isoproter-
enol in the presence of 10 WM forskolin increased by 1000-fold
intracellular cAMP values (Fig. 2A). The same e¡ect was
observed in the absence of IBMX (data not shown).
3.4. ATPQS-induced rise in intracellular cAMP is not sensitive
to a Gi protein
We next considered the possibility that the purinergic stim-
ulation blocks the activity of an inhibitory Gi protein. To test
this hypothesis, cells were incubated for 10 min with 100 WM
adenosine to switch on Gi protein activity and then stimulated
for 5 min in the sustained presence of adenosine with 10 nM
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Fig. 2. ATP and isoproterenol use di¡erent pathways to increase in-
tracellular cAMP content. A: Synergistic e¡ect of forskolin on iso-
proterenol- but not on ATP-induced cAMP increase. Adult rat car-
diomyocytes were incubated for 10 min in the presence of IBMX
and then stimulated for 5 min with 100 WM ATPQS, 1 WM isopro-
terenol in the presence or absence of forskolin (Forsk, 10 WM). B:
Control cells or cells treated for 20 h with 100 ng pertussis toxin
were incubated for 5 min with IBMX in the presence or absence of
100 WM adenosine and then stimulated for 5 min with 100 WM
ATPQS or/and 10 nM isoproterenol in the sustained presence or ab-
sence of adenosine. C: IBMX-treated cells were incubated for 5 min
in the absence or presence of 100 WM carbachol and were then
stimulated for 5 min with 100 WM ATPQS or/and 10 WM forskolin
in the sustained presence or absence of carbachol. Results are dupli-
cates from three cell preparations. Statistically signi¢cant, *P9 0.05;
**P9 0.01.
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isoproterenol or 100 WM ATPQS. Adenosine decreased basal
cAMP content that suggests that a Gi protein is slightly but
sustainedly activated in cardiomyocytes as already observed
[25]. Adenosine decreased by 2-fold the isoproterenol enhanc-
ing e¡ect on intracellular cAMP values but it did not signi¢-
cantly a¡ect the stimulatory e¡ect of ATPQS (Fig. 2B). Fur-
thermore, ATPQS relieved the adenosine inhibition of
isoproterenol e¡ect. As another approach to test the putative
involvement of a Gi protein in the e¡ect of ATPQS on intra-
cellular cAMP content, cells were treated with pertussis toxin
(PTX, 300 ng/ml for 4 h or 100 ng/ml for 20 h) at 37‡C. Such
a treatment increased basal intracellular cAMP value (26 þ
5 vs. 10 þ 1 pmol/mg protein, n = 6), which con¢rms the sus-
tained activation of a Gi protein under control conditions. In
PTX-treated cells, ATPQS was as much e⁄cient as in non-
treated cells to increase intracellular cAMP content (Fig.
2B). However, in PTX-treated cells, adenosine still slightly
decreased the isoproterenol e¡ect on intracellular cAMP con-
tent although this inhibitory e¡ect was less pronounced than
in non-treated cells (compare Fig. 2B middle and right pan-
els). The e⁄ciency of the PTX treatment of cells was further
checked by stimulating both non-treated and PTX-treated
cells with isoproterenol in the absence or in the presence of
the muscarinic agonist carbachol which also activates the Gi
protein. Carbachol abolished isoproterenol e¡ect in control
cells but not in PTX-treated cells (data not shown). This ¢nd-
ing con¢rms that the PTX-treatment of cells was suitable to
inhibit Gi protein activity. Although ATPQS was quite speci¢c
of P2-purinoceptors, it is still possible that the e¡ect of ATPQS
on adenosine-treated cells resulted from a displacement of
adenosine from its receptor. Thus, similar experiments were
carried out using the muscarinic agonist, carbachol, as an
activator of the Gi protein. Like adenosine, the muscarinic
agonist did not inhibit ATPQS e¡ect on cAMP (data not
shown). As expected, carbachol inhibited forskolin-induced
cAMP increase in cardiomyocytes. However, ATPQS partially
relieved this inhibition (Fig. 2C).
3.5. ATPQS speci¢cally stimulates adenylyl cyclase V
Our data strongly suggested that ATP activates an adenylyl
cyclase isoform that is not inhibited by a Gi protein and that
did not display a synergism between forskolin and Ks. To
identify the adenylyl cyclase(s) isoform(s) that is (are) turned
on by either the purinergic or the L-adrenergic stimulation, we
used transiently transfected HEK 293 cells. These cells share
at least two P2Y purinergic receptors (P2Y1 and P2Y2) with
cardiomyocytes [26,4], and express GKs45 and GKs52, but a
low level of endogenous type I, II, III, VI and VIII adenylyl
cyclase activities [27]. They were thus transfected with plas-
mids encoding adenylyl cyclase type IV, V and VI adenylyl
cyclases, the three isoforms expressed in cardiomyocytes [28].
In pcDNA (empty vector) transfected cells, the purinergic
agonist did not a¡ect intracellular cAMP content while iso-
proterenol increased it by 5-fold. In cells transfected with
plasmids encoding type IV or VI, isoproterenol increased by
30^60-fold intracellular cAMP con¢rming the expression of
the cyclases while ATP had no e¡ect on the intracellular cyclic
nucleotide level. By contrast, in cells expressing type V ad-
enylyl cyclase, the purinergic stimulation increased by 5^10-
fold and isoproterenol by 60-fold intracellular cAMP (Fig. 3).
4. Discussion
ATP is coreleased with noradrenaline from sympathetic
nerves. It is thus of physiological relevance to establish
whether the purinergic agonist could modulate the same trans-
duction pathway as the one of the L-adrenergic agonist,
namely the formation of cAMP. We found that ATPQS used
as a speci¢c P2-purinergic agonist signi¢cantly increases intra-
cellular cAMP content of isolated cardiomyocytes. The en-
hancing e¡ect of the purine on intracellular cAMP is observed
when cells are treated with IBMX, or milrinone and RO-20-
1724, three potent inhibitors of all phosphodiesterase iso-
forms. Thus, ATPQS does not exert its action through inhib-
ition of phosphodiesterases but rather stimulates adenylyl cy-
clase activity. The purinergic e¡ect is additive to the L-
adrenergic e¡ect on intracellular cAMP content. These results
suggest that the purinergic receptor does not share the same
pathway as the one that couples the L-adrenergic receptor to
adenylyl cyclase raising the question as to purinergic and L-
adrenergic stimulations di¡erentiate at the level of the G pro-
tein or of the adenylyl cyclase.
ADP-ribosylation by cholera toxin of Gs protein from
membrane prepared from ATPQS-stimulated cells shows that
like L-adrenergic receptor, the purinergic receptor is somehow
coupled to the 45 kDa Ks subunit. Purinergic and adrenergic
e¡ects on subsequent ADP-ribosylation of Ks by the toxin are
not additive indicating that both neurohormonal stimulations
share the same pool of Gs proteins. Although neonatal car-
diomyocytes predominantly feature the expression of 52 kDa
GKs subunit, the purinergic agonist also increases intracellular
cAMP in the cells. Thus, the 45 kDa protein is not speci¢cally
required by the purinergic receptor to activate adenylyl cy-
clase(s).
Pertussis toxin treatment of cells slightly increases basal
cAMP content but does not prevent ATPQS enhancing e¡ect
on intracellular cAMP. Thus, a relief of Gi protein inhibitory
tone does not mediate the purinergic e¡ect on intracellular
cAMP level. The data rather further point to a requirement
of a Gs protein in the purinergic transduction pathway that
generates cAMP. In contrast to isoproterenol, the e¡ect of
ATPQS on intracellular cAMP content is not counteracted
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Fig. 3. E¡ects of ATPQS and isoproterenol on intracellular cAMP
of HEK cells overexpressing speci¢c adenylyl cyclase isoforms.
HEK 293 cells were transfected with plasmids encoding type IV, V
or VI adenylyl cyclase or with empty pcDNA vectors. Cells were
then stimulated 48 h later with either ATPQS (100 WM) or isoproter-
enol (1 WM) in the presence of 100 WM IBMX. Statistically signi¢-
cant, **P9 0.01.
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by adenosine or muscarinic stimulation of myocytes. At ¢rst
glance, this observation suggests that the adenylyl cyclase iso-
form that is activated by purinergic stimulation is not sensitive
to Gi protein and is thus di¡erent from the one activated by
the L-adrenergic stimulation. Such a hypothesis is strength-
ened by the observation that purinergic stimulation of cardi-
omyocytes relieves adenosine- and carbachol-mediated inhib-
ition of isoproterenol or forskolin e¡ect on intracellular
cAMP. Although type II adenylyl cyclase is not sensitive in
vitro to Gi protein inhibition [29] it is unlikely to be the iso-
form activated by the purinergic stimulation; this isoform is
poorly if not at all expressed in cardiomyocytes [28,29]. In
addition, type II adenylyl cyclase is stimulated by PKC, a
stimulation that could not be observed in cardiomyocytes
(data not shown, [30]). Rather, type V adenylyl cyclase comes
out as a better candidate for two reasons. First, this isoform is
inhibited in vitro by Gi protein to a lesser extent and for a
greater Gi protein concentration than type VI [31]. Second, Gi
protein-induced inhibition of type V is dramatically reduced
in vitro when the cyclase is activated by Gs [31], a situation
similar to the physiological L-adrenergic stimulation (see Fig.
2).
Forskolin exerts a synergistic e¡ect on isoproterenol-medi-
ated increase in cAMP. This con¢rms the data reported by
Fischmeister and Schrier [32] in frog cardiomyocytes and
more recently by Post et al. [30] in rat cardiomyocytes. Such
an e¡ect can be explained by an enhancement in Ks subunits
a⁄nity for adenylyl cyclase that has already bound forskolin.
We demonstrate that forskolin does not have the ability to
potentiate ATPQS e¡ect on intracellular cAMP. Because only
type II, V and VI adenylyl cyclases display enhanced Ks bind-
ing by forskolin [33], it further brings evidence that type V
and VI are the most predominant isoforms in cardiomyocytes
and that the cyclase activity of one of them is turned on by
the purinergic stimulus [30]. If the purinergic receptor targets
speci¢cally type V adenylyl cyclase, the limited availability of
this isoform could also explain the weaker e¡ect of purinergic
stimulation on intracellular cAMP content when compared to
the L-adrenergic stimulation and the absence of forskolin po-
tentiation on purinergic e¡ect.
Using HEK 293 cells that share at least two P2Y subtypes of
receptors with cardiomyocytes [4,26] to express cardiac ad-
enylyl cyclase isoforms, we found that the type V but not
IV or VI of adenylyl cyclase is responsive to the purinergic
stimulation while all three adenylyl cyclase isoforms are acti-
vated by the L-adrenergic stimulation. A lower number of
purinergic receptors than of L-adrenergic receptors in HEK
cells might account for the weaker e¡ect of ATPQS than the
one of isoproterenol on cAMP in adenylyl cyclase V trans-
fected cells. We thus propose that the purinergic receptor like
the EGF receptor [34] is speci¢cally coupled through a Gs
protein to type V adenylyl cyclase in cardiac cells. This state-
ment also argues in favor of a poor Gi sensitivity of this iso-
form in cardiac cells in vivo.
We thus have demonstrated that purinergic stimulation of
cardiomyocytes increases intracellular cAMP content through
a Gs-mediated activation of an adenylyl cyclase isoform di¡er-
ent from the one involved in the L-adrenergic stimulation. Our
¢ndings open an interesting issue namely the coupling of a Gs
protein isoform to a speci¢c adenylyl cyclase isoform. It re-
mains to be determined how stimulation of Gs proteins
through a receptor targets a speci¢c isoform of adenylyl cy-
clase. A speci¢c intracellular localization of adenylyl cyclase
isoforms may account for such a targeting. Speci¢c anti-cy-
clase isoform antibodies are required to test this hypothesis.
Di¡erential activation of adenylyl cyclase isoforms by Gs pro-
teins (e.g. di¡erent interaction sites Gs/cyclase) may also ex-
plain a speci¢c activation of a cyclase isoform by an agonist
[34^36]. Furthermore, we report that the purinergic activation
of adenylyl cyclase adds to the L-adrenergic e¡ect. That ob-
servation suggests that the purine might be a modulator of
cell function already regulated by other neuromediators re-
leased from the same nerve terminals. Purine-induced increase
in intracellular cAMP might also serve as a safety mechanism
when the L1-adrenergic stimulation is desensitized as observed
in heart failure [37]. In the same line, purinergic stimulation of
a Gi-insensitive adenylyl cyclase could be bene¢cial for the
failing heart featuring an overexpression of Gi [37]. In aging,
a process during which the L-adrenergic stimulation is also
decreased and whole adenylyl cyclase activity decreased, ex-
pression of adenylyl cyclase V increases [38]. Thus, under this
physiological state the purinergic stimulation of adenylyl cy-
clase V could partially rescue the cAMP signal transduction
pathway.
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